{"entity":{"id":"nct06430866","kind":"trial","name":"Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)","aka":["Eucalyptus"],"tldr":"A phase 3 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Amgen, active and no longer recruiting.","summary":"Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) is a phase 3 interventional study registered as NCT06430866 by Amgen, with 163 participants enrolled, started 2024-09-12 and due to reach its primary completion in 2026-12-14. Interventions recorded: ABP 234, Pembrolizumab. Conditions listed: Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06430866","url":"https://clinicaltrials.gov/study/NCT06430866"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06430866","phase":"3","setting":"A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pembrolizumab) in Participants With Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy","sponsor":"Amgen","started":"2024-09-12","startedType":"actual","enrolled":163,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06430866/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}]}}